EUVIMEDEUVIMED entdecken
KohortenstudieOpen Access · CC BY-NC-ND 4.0

Efficacy and related factors of levonorgestrel‐releasing intrauterine system combined with metformin in fertility‐preserving treatment for atypical endometrial hyperplasia and early endometrial cancer: A retrospective cohort study

Pengpeng Gu, Jialu Gao, Yuxin Li, Mei Huang, Xiaoshuang Wang, Xin Zhao iD

International Journal of Gynecology & Obstetrics · 2026

DOI: 10.1002/ijgo.71037 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift International Journal of Gynecology & Obstetrics, 2026. Verfasst von Pengpeng Gu und 5 weiteren Autor:innen. Beteiligte Einrichtung: Postgraduate Training Base of Shenyang Women's and Children's Hospital of Jinzhou Medical University, Shenyang, Liaoning Province, China. Hauptthemen laut MEDLINE: Levonorgestrel, Endometrial Hyperplasia, Metformin, Endometrial Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Youth and Middle-aged Scientific and Technological Innovation Leading Talents Program of the Corps.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

To compare the efficacy of the levonorgestrel‐releasing intrauterine system combined with metformin versus oral progestin combined with metformin in fertility‐preserving treatment for patients with atypical endometrial hyperplasia and early endometrial cancer, and to analyze related factors affecting efficacy.

Methods

From January 2015 to December 2023, clinical data of patients with atypical endometrial hyperplasia or early endometrial cancer were retrospectively analyzed. Patients were divided into a study group and a control group based on treatment method. Complete remission rate, remission time, recurrence rate, pregnancy outcomes, and adverse reactions were compared between groups. Multivariate logistic regression was used to identify factors associated with complete remission, recurrence, and pregnancy.

Results

Post‐treatment endometrial thickness decreased in both groups compared with pre‐treatment levels, with a greater reduction in the study group than the control group. Compared with the control group, the study group demonstrated a higher complete remission rate at 3, 6, 9, and 12 months, shorter time to onset and time to complete remission, lower recurrence rate, higher pregnancy and live birth rates, and lower incidence of adverse reactions. Multivariate logistic regression analysis identified age 35 years or older, body mass index (BMI) of 28 or greater, polycystic ovary syndrome, and pathologic type of endometrial cancer as risk factors for complete remission. BMI of 28 or greater and pathologic type of endometrial cancer were risk factors for recurrence. Age 35 years or older and BMI 28 or greater were risk factors for pregnancy. BMI stratification analysis demonstrated that patients with lower BMI achieved better treatment outcomes.

Conclusions

This retrospective study preliminarily suggests that the levonorgestrel‐releasing intrauterine system combined with metformin shows a trend toward better treatment response in fertility‐preserving treatment, manifested by higher complete remission rates, shorter time to remission, lower recurrence rates, and favorable pregnancy outcomes. In addition, obesity, age of 35 years or older, polycystic ovary syndrome, and pathologic type of endometrial cancer were identified as factors influencing treatment response.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

LevonorgestrelEndometrial HyperplasiaMetforminEndometrial NeoplasmsFertility PreservationIntrauterine Devices, MedicatedHumansFemaleRetrospective StudiesAdultPregnancyProgestinsTreatment OutcomePregnancy OutcomePregnancy Rate

Stichwörter der Autor:innen

atypical endometrial hyperplasiaearly endometrial cancerfertility‐preserving treatmentlevonorgestrel‐releasing intrauterine systemmetformin

Substanzen

LevonorgestrelMetforminProgestins

Autor:innen und Institutionen

  • Postgraduate Training Base of Shenyang Women's and Children's Hospital of Jinzhou Medical University, Shenyang, Liaoning Province, China.
  • Shenyang Women's and Children's Hospital, Shenyang, Liaoning Province, China.

ORCID-Profile: Xin Zhao

Förderung

  • Youth and Middle-aged Scientific and Technological Innovation Leading Talents Program of the Corps

Zitieren

APA

Gu, P., Gao, J., Li, Y., Huang, M., Wang, X., & Zhao, X. (2026). Efficacy and related factors of levonorgestrel‐releasing intrauterine system combined with metformin in fertility‐preserving treatment for atypical endometrial hyperplasia and early endometrial cancer: A retrospective cohort study. International Journal of Gynecology & Obstetrics. https://doi.org/10.1002/ijgo.71037

Vancouver

Gu P, Gao J, Li Y, Huang M, Wang X, Zhao X. Efficacy and related factors of levonorgestrel‐releasing intrauterine system combined with metformin in fertility‐preserving treatment for atypical endometrial hyperplasia and early endometrial cancer: A retrospective cohort study. International Journal of Gynecology & Obstetrics. 2026. doi:10.1002/ijgo.71037

BibTeX
@article{Gu2026,
  author = {Gu, Pengpeng and Gao, Jialu and Li, Yuxin and Huang, Mei and Wang, Xiaoshuang and Zhao, Xin},
  title = {Efficacy and related factors of levonorgestrel‐releasing intrauterine system combined with metformin in fertility‐preserving treatment for atypical endometrial hyperplasia and early endometrial cancer: A retrospective cohort study},
  journal = {International Journal of Gynecology & Obstetrics},
  year = {2026},
  doi = {10.1002/ijgo.71037}
}
Kostenlos starten →